Showing its confidence in SQZ’s intracellular delivery platform, Roche has expanded its research collaboration with the company and paid US$125 M in upfront and near-term payments to co-develop and co-commercialise antigen presenting cell therapies for the treatment of oncology indications. The agreement builds on the 2015 collaboration between the two companies focused on delivering tumour-associated antigens into B cells extracted from patients using SQZ’s technology in a deal worth US$500 M in upfront and potential clinical, regulatory and sales milestone-based payments.